Related references
Note: Only part of the references are listed.Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
Jennie H. Best et al.
DIABETES CARE (2011)
Single Dose GLP-1-Tf Ameliorates Myocardial Ischemia/Reperfusion Injury
Muneaki Matsubara et al.
JOURNAL OF SURGICAL RESEARCH (2011)
GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells
Fei Yin et al.
ACTA PHARMACOLOGICA SINICA (2010)
Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
Ted Okerson et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Mads Halbirk et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
Yumei Ye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Mathijs C. Bunck et al.
ATHEROSCLEROSIS (2010)
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
Yuji Ishibashi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats
S. M. Gardiner et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
Que Liu et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
Anne Gill et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Neonatal Exendin-4 Leads to Protection from Reperfusion Injury and Reduced Rates of Oxidative Phosphorylation in the Adult Rat Heart
Suzanne B. Brown et al.
CARDIOVASCULAR DRUGS AND THERAPY (2010)
DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
Philip A. Read et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2010)
Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy
Siva Bhashyam et al.
CIRCULATION-HEART FAILURE (2010)
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome
David S. Tofovic et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2010)
Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Vasilios G. Athyros et al.
CURRENT DRUG TARGETS (2010)
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Masayuki Arakawa et al.
DIABETES (2010)
Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
Meghan Sauve et al.
DIABETES (2010)
The synthetic GLP-1 receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats
Subramanyam N. Murthy et al.
DIABETES & VASCULAR DISEASE RESEARCH (2010)
Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes
Juraj Koska et al.
DIABETES CARE (2010)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
被撤回的出版物: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells (Retracted article. See vol. 55, pg. 533, 2012)
Y. Hattori et al.
DIABETOLOGIA (2010)
EFFECTS OF COLESEVELAM, ROSIGLITAZONE, OR SITAGLIPTIN ON GLYCEMIC CONTROL AND LIPID PROFILE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY METFORMIN MONOTHERAPY
Scott. P. Rigby et al.
ENDOCRINE PRACTICE (2010)
Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
Kiwon Ban et al.
ENDOCRINOLOGY (2010)
Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) - Rationale, design and first interim analysis
Hans D. Theiss et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia
Adam M. Deane et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress
Jianfei Chen et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2010)
GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
Hui-Chun Ku et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2010)
Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
PHARMACOTHERAPY (2010)
Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications
Corey E. Tabit et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2010)
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
Eva Tomas et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression
Le Thi Kim Chung et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
Kunio Hirata et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model
Jens Kristensen et al.
BMC CARDIOVASCULAR DISORDERS (2009)
Role of Glycogen Synthase Kinase-3β in Cardioprotection
Magdalena Juhaszova et al.
CIRCULATION RESEARCH (2009)
A Review of Efficacy and Safety Data Regarding the Use of Liraglutide, a Once-Daily Human Glucagon-Like Peptide 1 Analogue, in the Treatment of Type 2 Diabetes Mellitus
Eduard Montanya et al.
CLINICAL THERAPEUTICS (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Defining and Characterizing the Progression of Type 2 Diabetes
Vivian A. Fonseca
DIABETES CARE (2009)
Exenatide: a review from pharmacology to clinical practice
R. Gentilella et al.
DIABETES OBESITY & METABOLISM (2009)
Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting
Rajat Bhushan et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2009)
STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL
Helena W. Rodbard et al.
ENDOCRINE PRACTICE (2009)
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
Hongbin Liu et al.
JOURNAL OF ENDOCRINOLOGY (2009)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Incretin-based therapies for type 2 diabetes mellitus
Julie A. Lovshin et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Mining incretin hormone pathways for novel therapies
Rhonda D. Wideman et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2009)
GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP
Brian D. Green et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Heme Oxygenase-1 Regulates Cardiac Mitochondrial Biogenesis via Nrf2-Mediated Transcriptional Control of Nuclear Respiratory Factor-1
Claude A. Piantadosi et al.
CIRCULATION RESEARCH (2008)
Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure-Prone Rat
Indu Poornima et al.
CIRCULATION-HEART FAILURE (2008)
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
Thomas J. Moretto et al.
CLINICAL THERAPEUTICS (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
J. -P. Courreges et al.
DIABETIC MEDICINE (2008)
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
M. Florentin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Endothelium-dependent vasodilation in conduit and resistance vessels in relation to the endothelial nitric oxide synthase gene
E. Ingelsson et al.
JOURNAL OF HUMAN HYPERTENSION (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart
David P. Sonne et al.
REGULATORY PEPTIDES (2008)
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride
Ananda Basu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Julio Rosenstock et al.
DIABETES CARE (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
George G. Sokos et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
George G. Sokos et al.
JOURNAL OF CARDIAC FAILURE (2006)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2006)
Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: Lessons from the San Luigi Gonzaga Diabetes Study
F Cavalot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function
Xiaoli Liu et al.
FASEB JOURNAL (2006)
The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease
SM Haffner
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
LA Nikolaidis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
The pathobiology of diabetic complications - A unifying mechanism
M Brownlee
DIABETES (2005)
The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
CR Abbott et al.
BRAIN RESEARCH (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
T Nyström et al.
REGULATORY PEPTIDES (2005)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model
AK Bose et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines
LA Nikolaidis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum
L Hansen et al.
REGULATORY PEPTIDES (2004)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway
DJ Hausenloy et al.
CARDIOVASCULAR RESEARCH (2004)
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
LA Nikolaidis et al.
CIRCULATION (2004)
Myocardial protection at a crossroads - The need for translation into clinical therapy
R Bolli et al.
CIRCULATION RESEARCH (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nyström et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
M Yu et al.
JOURNAL OF HYPERTENSION (2003)
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
JJ Meier et al.
DIABETOLOGIA (2003)
Cardiac function in mice lacking the glucagon-like peptide-1 receptor
R Gros et al.
ENDOCRINOLOGY (2003)
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
M Kavianipour et al.
PEPTIDES (2003)
Influence of weight reduction on blood pressure - A meta-analysis of randomized controlled trials
JE Neter et al.
HYPERTENSION (2003)
Renal effects of glucagon-like peptide in rats
C Moreno et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat
HA Golpon et al.
REGULATORY PEPTIDES (2001)
Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence
E Bonora et al.
DIABETOLOGIA (2001)
Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes
MGV Petroff et al.
CIRCULATION RESEARCH (2001)
Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C
HY Tong et al.
CIRCULATION RESEARCH (2000)
Share Paper
